SynthesisBritish journal of cancer2009
Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events.
Synthesis in British journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data.British journal of cancer · 2014Pooled it
- Erythropoietin or darbepoetin for patients with cancer.The Cochrane database of systematic reviews · 2012Pooled it
- Experimental Drugs for Chemotherapy- and Cancer-Related Anemia.Journal of experimental pharmacology · 2021Review
- Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach.Frontiers in physiology · 2018Review
- Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions.British journal of clinical pharmacology · 2016Article
- Epoetin beta for the treatment of chemotherapy-induced anemia: an update.OncoTargets and therapy · 2015Review
- Erythropoietin Combined with Liposomal Amphotericin B Improves Outcome during Disseminated Aspergillosis in Mice.Frontiers in immunology · 2014Article
- Erythropoietin and cancer: the unintended consequences of anemia correction.Frontiers in immunology · 2014Review
- Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013Review
- Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.British journal of cancer · 2012Review
- Falls in nursing home residents receiving pharmacotherapy for anemia.Clinical interventions in aging · 2012Article
- Clinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia.Cancer management and research · 2011Article
- Regarding: 'Epoetin beta treatment in patients with cancer chemotherapy induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events'.British journal of cancer · 2009Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpoetin-beta is used to treat patients with cancer undergoing chemotherapy to alleviate the symptoms of anaemia, reduce the risk of blood transfusions and improve quality of life (QoL).
methodsThis meta-analysis of all 12 randomised, controlled studies of epoetin-beta evaluated the impact of therapy at different Hb-initiation levels and to different target Hb levels on overall survival, tumour progression and thromboembolic events (TEE). An analysis of risk factors pre-disposing patients to TEEs under epoetin-beta therapy was also performed. A total of 2297 patients are included in the analysis.
resultsAnalyses based on various Hb-initiation levels indicate no detrimental impact on survival (HR 0.99; 95% CI 0.70, 1.40) and a favourable impact on disease progression (HR 0.73; 95% CI 0.57, 0.94) when epoetin-beta was used within its licensed indication (Hb initiation < or = 10 g dl(-1)) or the EORTC recommended level of 11 g dl(-1). An increased risk of TEEs is seen for all Hb-initiation level strata and a detrimental impact on survival is seen when initiating epoetin-beta therapy at Hb levels >11 g dl(-1). We observe no association between high target Hb levels (> or = 13 g dl(-1)) and an increased risk of mortality, disease progression or TEEs with epoetin-beta compared with control.
conclusionThe results of this analysis indicate that epoetin-beta therapy has no detrimental impact on survival or tumour progression when initiated at Hb levels up to 11 g dl(-1). Furthermore, there is no evidence to suggest that high Hb values achieved during epoetin-beta therapy are associated with an increased mortality, disease progression or TEE rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.